Editorial

Referral Criteria for Chronic Obstructive Pulmonary Disease: A Proposal of Continuity of Care

Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic process that presents a real challenge for health care systems. Numerous factors have contributed to the growing problem, such as tobacco use at earlier ages, increased numbers of active smokers, and environmental pollution. The aging population, which presents multiple associated pathologies and consumes enormous health resources, also plays a role in rising physical and financial health costs.\(^1\)

The rate of underdiagnosis is high,\(^1\) as is the degree of disability caused by COPD, which exerts considerable pressure on hospitals and primary care.\(^3,4\) The difficulties in treating and following up these patients make it necessary to develop clinical practice guidelines (CPGs) that guarantee adequate continuity of care when patients transition to different levels of care.

Despite great efforts to improve the management of patients with COPD, the low implementation of spirometry\(^4,5\) and the irregularity and heterogeneity of follow-up continue to be two particularly critical points to be resolved. In addition, there are other important issues to address, such as adherence to CPGs, promotion of health education and air quality control.\(^2\) However, the recognized role of forced spirometry in the diagnosis of the disease, as well as its limited use, are topics that are widely addressed in different documents and CPGs.\(^6-8\) Furthermore, the information that we can obtain about how patients should be monitored beyond a therapeutic approach is scarce.

With the intention of improving the continuity of care for these patients, different integrated care processes (ICPs) have been prepared with little success. Focusing specifically on monitoring patients with COPD, the health care schemes proposed by ICPs are quite rigid. For example, the assessment intervals are based on the severity of the process (e.g., degree of obstruction to airflow) and risk of complications as determined by the Spanish Guide of Chronic Obstructive Pulmonary Disease (GeSPOC) and are not adjusted according to the individual patient’s clinical changes. Furthermore, recommendations on the follow-up care of patients with stable COPD have little bibliographic support, given the contradictory results of studies that have evaluated different “care formulas”.\(^9-10\)

To facilitate the continuity of care for patients with COPD, the document “Referral criteria for COPD: Continuity of care\(^11\)” is a practical guide that has been prepared by scientific societies whose members care for patients with this disease. The guide describes in detail the initial diagnostic assessment, the treatment of the patient with COPD and follow-up. With respect to this last point, the objective should be to guarantee the well-being of the patient and optimize the available resources, so collaboration and communication between hospitals and primary care must be fluid. However, both in COPD and in other respiratory diseases, patients’ transition from hospitals to primary care providers has not been smooth. Instead, patients have not received comprehensive care, and scheduled consultations have been delayed, necessitating frequent visits to the emergency room; furthermore, miscommunications have led to duplicated consultations and tests.\(^12\) To resolve these problems, we consider that there are four key points to assess:\(^11\) control of symptoms, prevention of exacerbations/search for aggravations, continuity in the evaluation of the inhalation technique/adherence to treatment and the monitoring of lung function.

From an organizational point of view, the improvement of symptoms and especially the prevention of exacerbations should determine follow-up intervals. The natural history of COPD is punctuated by frequent periods of exacerbation, which in some cases lead to hospitalization.\(^12\) These episodes produce a substantial deterioration in the quality of life of the patient, an increase in their risk of morbidity and mortality, and great health care costs.\(^2\) Consequently, identifying the patients who are most susceptible to exacerbation is a priority. The questionnaire proposed by GeSPOC in its 2021 edition\(^16\) has proven to be sensitive to clinical changes in the patient and is capable of predicting exacerbations in a relatively short period. Thus, those patients with COPD labeled as “poorly controlled” have a greater risk of suffering an exacerbation in the following 3–6 months,\(^13\) a situation that would support the need to reduce follow-up intervals. These changes are not exclusive to patients with more advanced COPD (high risk according to GeSPOC 2021) but may also be present in patients with less complexity (low risk according to GeSPOC 2021).\(^14\) Therefore, the degree of control can be a tool in the management of patients regardless of the severity of the disease.

Factors such as the presence of comorbidities (especially those of a cardiovascular nature), the social situation of the patient, failures in the inhalation technique or poor adherence to CPGs have been related to a greater deterioration in the patient’s quality of life, missed primary care visits and an increase in health spending.\(^2\) All these aspects should be reviewed at each visit, especially for individuals for whom clinical control has not been achieved.

For patients who are fragile or have mobility issues, telephone follow-up could be a complementary activity to face-to-face visits,\(^9\) allowing health care providers to promote self-management, regular physical activity or early recognition of an exacerbation.

Information on lung function monitoring is scarce.\textsuperscript{6–8} Current evidence supports the performance of an annual physical examination in the first three years after diagnosis, with the intention of identifying those patients with an accelerated decline in lung function. Beyond this recommendation, the evidence is insufficient. Forced expiratory volume in the first second (FEV\textsubscript{1}) has been recognized as an important prognostic factor. Therefore, our opinion is that follow-up visits to take this measurement should be carried out every two to three years,\textsuperscript{11} unless changes are made to the treatment, in which case consultations should be conducted every three months. FEV\textsubscript{1} and chest X-ray are recommended in situations of clinical deterioration or only slight improvement after the appropriate treatment or an adjustment to treatment. Based on all this, the document on referral criteria for COPD proposes the scheme shown in Fig. 1.

Regarding the indicators to refer a patient to the next level of care after the diagnosis of COPD, there is no standardization. The decision to refer depends not only on the clinical situation of the patient but also on other aspects, such as the experience of the health care professionals, the resources of the health center, the possibilities of follow-up and the distance from the home to the health center or hospital. Table 1 proposes a series of indicators that can help us in this regard.

In the recently published document on referral criteria for patients with COPD,\textsuperscript{11} the proposed follow-up guidelines have been agreed upon by hospitals and primary care providers. We...
firmly believe that our proposal will be well received, both by the health professionals who care for these patients and by the hospital administrators responsible for establishing the necessary resources to guarantee adequate quality of care.

Authors’ contributions

Each author declares they have made an individual contribution to the article, all of them have materially participated in the research and/or preparation of the article.

Approval

All authors have authorized its publication.

Funding

All authors declare that there is no funding in this manuscript.

Conflict of interest

Javier de Miguel-Diez has received honoraria and funding from laboratorios AstraZeneca, Bial, Boehringer, Chiesi, Esteve, FAES, Ferrer, Gebro Pharma, GlaxoSmithKline, Janssen, Menarini, MundiPharma, Novartis, Roche, Rovi, Teva y Pfizer. Juan Marco Figueira Gonçalves has received honoraria for speaking engagements and funding for conference attendance from laboratorios Esteve, MundiPharma, AstraZeneca, Boehringer Ingelheim, Ferrer, Menarini, Rovi, GlaxoSmithKline, Chiesi, Novartis, and Gebro Pharma. Francisco Javier Plaza Zamora has received honoraria for speaking engagements and funding from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, and Teva. María Sanz Almazán has received honoraria for speaking engagements and funding for conference attendance from laboratorios Menarini, GlaxoSmithKline, Vifor Pharma, AstraZeneca, Novo Nordisk, and Bial. Eva Trillo Calvo has received honoraria for speaking engagements and funding for conference attendance from laboratorios Menarini, GlaxoSmithKline, AstraZeneca, Lundbeck, Esteve, FAES, Boehringer Ingelheim, and Servier. Marta Villanueva Pérez has received honoraria for speaking engagements and funding from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Teva. Juan Enrique Cimás has received honoraria in the last three years for spirometry and COPD courses from semfyc and SESP.

References


Javier de Miguel-Diez a,b, Juan Marco Figueira-Gonçalves c,d, Eva Trillo-Calvo e, Juan Enrique Cimás-Hernando f, Marta Villanueva-Pérez g, Francisco Javier Plaza-Zamora h, María Sanz-Almazán a

a Pneumology Service of Hospital General Universitario Gregorio Marañón, Institute of Health Research Gregorio Marañón (IISGM), Madrid, Spain
b Universidad Complutense de Madrid, Madrid, Spain
c Respiratory Department, Research Unit, Hospital Universitario Nuestra Señora de Candelaria, La Laguna, Spain
d Canary Tropical Disease and Public Health Institute, Universidad de La Laguna, San Cristóbal de la Laguna, Spain
e Aragonese Health Service, Primary Care, Centro de Salud Campo de Belchite, Zaragoza, Spain
f Centro de Salud de Conteruces-Vega, Asturias, Spain
g EAP Ribes-Olivella (SAP Alt Penedès Garraf), Institut Català de la Salut, Tarragona, Spain
h Farmacia Zamora, Murcia, Spain
i Centro de Salud De Riaza, Segovia, Spain

* Corresponding author.
E-mail address: juanmarcofigueira@gmail.com (J.M. Figueira-Gonçalves).